← Back to Analyst Consensus 
LBRX Buy
LB PHARMACEUTICALS INC
Current Price —
Implied Upside —
Analysts 15
30-Day Momentum
▲ 3 upgrades / ▼ 1 downgrades / 0 reiterations from 4 firms
Next Earnings
Nov 5, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 9, 2026 | Canaccord Genuity | initiate | — → Buy | — | 48% |
| Oct 6, 2026 | Guggenheim | initiate | — → Buy | — | 52% |
| Oct 5, 2026 | Roth Capital | downgrade | Buy → Neutral | — | 53% |
| Oct 2, 2026 | Needham | initiate | — → Buy | — | 50% |
| Aug 24, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Aug 12, 2026 | BMO Capital | maintain | Outperform → Outperform | — | 53% |
| Aug 3, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jul 21, 2026 | BMO Capital | initiate | — → Outperform | — | 53% |
| Jul 7, 2026 | Wolfe Research | initiate | — → Outperform | — | 53% |
| Apr 27, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| Apr 10, 2026 | Craig-Hallum | initiate | — → Buy | — | 54% |
| Mar 27, 2026 | Stifel | maintain | Buy → Buy | — | 53% |
| Dec 11, 2025 | Stifel | maintain | Buy → Buy | $35 | 53% |
| Oct 6, 2025 | Stifel | initiate | — → Buy | $27 | 53% |
| Oct 6, 2025 | Piper Sandler | initiate | — → Overweight | $78 | 54% |
| Oct 6, 2025 | Leerink Partners | initiate | — → Outperform | $34 | 51% |
Price Target Trend
Mar 26, 2026 Oct 26, 2026
EPS Estimates
+1q —
+1y —
0q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days